Skip to content

19-398 - An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Status: open

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Contact Us Or call +1 (251) 665-8375


This is a phase 3 efficacy and safety study of Ravulizumab in adults with neuromyelitis optica spectrum disorder (NMOSD). The goal is to provide NMOSD patients another treatment option for their condition that reduces treatment burden while maintaining a comparable risk/benefit profile.


This trial is sponsored by Alexion Pharmaceuticals.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.